Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
5 evidence topics · 8 sources
Himalayas-1 objective and endpoints
Company-stated therapeutic goal
Company benchmark for approved post-ARPI therapies
Control-arm outcomes with an alternative ARPI or docetaxel after a first ARPI
US real-world outcomes after a prior androgen receptor pathway inhibitor
“In the overall population, median time on the index therapy and median time from index therapy to next therapy were 4.1 and 6.2 months, respectively. Median overall survival and radiographic progression-free survival from the initiation of index therapy were 15.1 and 7.0 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time from start of 1 L to next LOT or end of follow-up was 13.7 months, 10.9 months from 2 L start, and 8.9 months from 3 L start.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median survival was 25.6 months after mCRPC and 23.4 months following treatment initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote